Collaboration and innovation lead to refilled drug pipeline

07/11/2011 | Wall Street Journal, The

A slew of best-selling drugs will soon lose patent protection, but innovative drugs in the pipeline are likely to receive FDA approval and could soften pharma's fall off the so-called patent cliff. Bristol-Myers Squibb moved to encourage collaboration with outside researchers, resulting in the development of an innovative drug that uses the immune system to target melanoma, said Elliott Sigal, Bristol's head of research and development. "We're seeing a lot of innovation, much more than in recent memory," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX